Brokers Issue Forecasts for PROCEPT BioRobotics Co.’s Q2 2025 Earnings (NASDAQ:PRCT)

PROCEPT BioRobotics Co. (NASDAQ:PRCTFree Report) – Equities research analysts at Leerink Partnrs issued their Q2 2025 EPS estimates for PROCEPT BioRobotics in a report released on Thursday, March 28th. Leerink Partnrs analyst M. Kratky expects that the company will post earnings of ($0.42) per share for the quarter. The consensus estimate for PROCEPT BioRobotics’ current full-year earnings is ($2.00) per share.

PROCEPT BioRobotics (NASDAQ:PRCTGet Free Report) last posted its quarterly earnings data on Tuesday, February 27th. The company reported ($0.54) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.10). PROCEPT BioRobotics had a negative net margin of 77.75% and a negative return on equity of 46.59%. The firm had revenue of $43.58 million for the quarter, compared to the consensus estimate of $41.79 million. During the same quarter last year, the firm earned ($0.56) EPS. The company’s revenue was up 83.3% on a year-over-year basis.

A number of other brokerages have also issued reports on PRCT. Wells Fargo & Company boosted their target price on shares of PROCEPT BioRobotics from $44.00 to $47.00 and gave the company an “overweight” rating in a research note on Tuesday, January 9th. Truist Financial boosted their target price on shares of PROCEPT BioRobotics from $55.00 to $58.00 and gave the company a “buy” rating in a research note on Wednesday, February 28th. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $45.60.

Read Our Latest Stock Analysis on PROCEPT BioRobotics

PROCEPT BioRobotics Trading Up 1.2 %

PRCT stock opened at $49.42 on Friday. The stock has a market capitalization of $2.52 billion, a price-to-earnings ratio of -22.06 and a beta of 1.02. PROCEPT BioRobotics has a twelve month low of $24.83 and a twelve month high of $52.32. The company has a quick ratio of 6.77, a current ratio of 7.63 and a debt-to-equity ratio of 0.18. The firm’s fifty day simple moving average is $48.47 and its two-hundred day simple moving average is $40.15.

Hedge Funds Weigh In On PROCEPT BioRobotics

Several hedge funds have recently modified their holdings of the stock. Legal & General Group Plc increased its holdings in shares of PROCEPT BioRobotics by 4.5% during the fourth quarter. Legal & General Group Plc now owns 6,843 shares of the company’s stock valued at $284,000 after acquiring an additional 295 shares in the last quarter. Amalgamated Bank increased its holdings in PROCEPT BioRobotics by 5.8% in the 4th quarter. Amalgamated Bank now owns 5,804 shares of the company’s stock worth $243,000 after buying an additional 316 shares during the period. Osaic Holdings Inc. increased its holdings in PROCEPT BioRobotics by 31.0% in the 2nd quarter. Osaic Holdings Inc. now owns 1,430 shares of the company’s stock worth $51,000 after buying an additional 338 shares during the period. Crossmark Global Holdings Inc. increased its holdings in PROCEPT BioRobotics by 3.1% in the 4th quarter. Crossmark Global Holdings Inc. now owns 12,088 shares of the company’s stock worth $507,000 after buying an additional 358 shares during the period. Finally, Credit Suisse AG increased its holdings in PROCEPT BioRobotics by 6.0% in the 3rd quarter. Credit Suisse AG now owns 7,594 shares of the company’s stock worth $314,000 after buying an additional 430 shares during the period. Institutional investors and hedge funds own 89.46% of the company’s stock.

Insider Buying and Selling

In related news, CFO Kevin Waters sold 28,677 shares of the company’s stock in a transaction dated Friday, February 9th. The shares were sold at an average price of $50.09, for a total value of $1,436,430.93. Following the completion of the sale, the chief financial officer now directly owns 33,523 shares of the company’s stock, valued at $1,679,167.07. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other PROCEPT BioRobotics news, CFO Kevin Waters sold 28,677 shares of the business’s stock in a transaction dated Friday, February 9th. The shares were sold at an average price of $50.09, for a total value of $1,436,430.93. Following the completion of the transaction, the chief financial officer now directly owns 33,523 shares in the company, valued at $1,679,167.07. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Alaleh Nouri sold 5,306 shares of the business’s stock in a transaction dated Wednesday, February 7th. The stock was sold at an average price of $49.95, for a total transaction of $265,034.70. Following the completion of the transaction, the executive vice president now owns 47,351 shares of the company’s stock, valued at $2,365,182.45. The disclosure for this sale can be found here. Insiders sold a total of 127,459 shares of company stock valued at $6,153,402 over the last three months. 19.60% of the stock is owned by company insiders.

About PROCEPT BioRobotics

(Get Free Report)

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).

Featured Articles

Earnings History and Estimates for PROCEPT BioRobotics (NASDAQ:PRCT)

Receive News & Ratings for PROCEPT BioRobotics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PROCEPT BioRobotics and related companies with MarketBeat.com's FREE daily email newsletter.